

Application No.: 10/001,469

Docket No.: 511582002420

AMENDMENTS TO THE CLAIMS

1-47. (canceled)

48. (currently amended): A method to identify an agent that decreases 101P3A11 protein activity, comprising:

- providing a first sample of cells and a second sample of cells, wherein the cells of each sample express 101P3A11;
- contacting the first sample with a candidate compound and
- measuring 101P3A11 protein activity in the first sample with the candidate compound;
- measuring 101P3A11 protein activity in the second sample, wherein the second sample has not been contacted with said candidate compound;
- comparing the measured 101P3A11 protein activity in said first and second samples;
- whereby a diminution in the 101P3A11 protein activity in said first sample as compared to said second sample identifies said compound as an agent that decreases 101P3A11 protein activity;
- wherein 101P3A11 protein is SEQ ID NO: 2866; and
- wherein said activity comprises 101P3A11-mediated cAMP accumulation or the downstream signaling effects thereof a downstream signaling effect thereof which is selected from the group consisting of:

101P3A11-mediated ERK phosphorylation;101P3A11-mediated p38 phosphorylation;101P3A11-mediated cell growth;101P3A11-mediated G-alpha subunit activation; and101P3A11-mediated cell adhesion.

49. (canceled)

50. (previously presented): The method of claim 48, wherein said cells have been modified to contain an expression system for said 101P3A11 protein.

Application No.: 10/001,469

Docket No.: 511582002420

51-53. (canceled)

54. (previously presented): The method of claim 48, wherein the candidate compound is an antibody that binds specifically to the 101P3A11 protein.

55-56. (canceled)

sd-306092

3